{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:17:48Z","timestamp":1787159868177,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:00:00Z","timestamp":1793059200000},"content-version":"am","delay-in-days":330,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jiac.2025.102838","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:57:30Z","timestamp":1761184650000},"page":"102838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and external validation of a population pharmacokinetic model and optimal Vancomycin dosing regimen for overweight and obese patients"],"prefix":"10.1016","volume":"31","author":[{"given":"Toshiaki","family":"Komatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-1237","authenticated-orcid":false,"given":"Masaru","family":"Samura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-7700","authenticated-orcid":false,"given":"Ayako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2689-5338","authenticated-orcid":false,"given":"Tomoyuki","family":"Ishigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0353-7933","authenticated-orcid":false,"given":"Satoshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7110-5166","authenticated-orcid":false,"given":"Yuta","family":"Ibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5597-2558","authenticated-orcid":false,"given":"Hiroaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Ebihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2702-5841","authenticated-orcid":false,"given":"Yusuke","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Nagumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitoshi","family":"Takuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Enoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Otori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-1684","authenticated-orcid":false,"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102838_bib1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102838_bib2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jiac.2025.102838_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical practice guidelines for therapeutic drug monitoring of Vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jiac.2025.102838_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing","volume":"21","author":"Tsutsuura","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2025.102838_bib5","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jiac.2024.05.014","article-title":"Validation and development of population pharmacokinetic model of vancomycin using a real-world database from a nationwide free web application","volume":"30","author":"Oda","year":"2024","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102838_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00007691-199804000-00003","article-title":"Population pharmacokinetics of vancomycin in Japanese adult patients","volume":"20","author":"Yasuhara","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2025.102838_bib7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s11095-021-03030-y","article-title":"Performance of area under the concentration-time curve estimations of Vancomycin with limited sampling by a newly developed web application","volume":"38","author":"Oda","year":"2021","journal-title":"Pharm Res"},{"key":"10.1016\/j.jiac.2025.102838_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000375143","article-title":"The global burden of obesity and the challenges of prevention","volume":"66","author":"Seidell","year":"2015","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.jiac.2025.102838_bib9","first-page":"8","article-title":"Effects of obesity on the cytochrome P450 enzyme system","volume":"37","author":"Kotlyar","year":"1999","journal-title":"Int J Clin Pharm Ther"},{"key":"10.1016\/j.jiac.2025.102838_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/js980173a","article-title":"Pharmacokinetic considerations in obesity","volume":"88","author":"Blouin","year":"1999","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jiac.2025.102838_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s002280050524","article-title":"Vancomycin dosing in morbidly obese patients","volume":"54","author":"Bauer","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2025.102838_bib12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1128\/AAC.21.4.575","article-title":"Vancomycin pharmacokinetics in normal and morbidly obese subjects","volume":"21","author":"Blouin","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102838_bib13","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/jac\/dks066","article-title":"Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years","volume":"67","author":"Grace","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102838_bib14","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1093\/jac\/dky310","article-title":"Dosing vancomycin in the super obese: less is more","volume":"73","author":"Crass","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102838_bib15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2146\/ajhp100410","article-title":"Determining vancomycin clearance in an overweight and obese population","volume":"68","author":"Leong","year":"2011","journal-title":"Am J Health Syst Pharm"},{"issue":"Suppl 2","key":"10.1016\/j.jiac.2025.102838_bib16","first-page":"51S","article-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in Adults--The evidence report","volume":"6","year":"1998","journal-title":"National Institutes Health Obes Res"},{"key":"10.1016\/j.jiac.2025.102838_bib17","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2025.102838_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.jiac.2025.102838_bib19","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jiac.2025.102838_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2014A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput Methods Progr Biomed"},{"key":"10.1016\/j.jiac.2025.102838_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jiac.2025.102838_bib22","article-title":"Population pharmacokinetics and dose optimization of voriconazole in patients with COVID-19-associated pulmonary aspergillosis","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiac.2025.102838_bib23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.jiac.2025.102838_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","article-title":"A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models","volume":"59","author":"Parke","year":"1999","journal-title":"Comput Methods Progr Biomed"},{"key":"10.1016\/j.jiac.2025.102838_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1364681","article-title":"Vancomycin population pharmacokinetics and dosing proposal for the initial treatment in obese adult patients","volume":"15","author":"Pol\u00e1\u0161kov\u00e1","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiac.2025.102838_bib26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/FTD.0000000000001214","article-title":"Developing parametric and nonparametric models for model-informed precision dosing: a quality improvement effort in Vancomycin for patients with obesity","volume":"46","author":"Hughes","year":"2024","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2025.102838_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40262-023-01324-5","article-title":"How to dose Vancomycin in overweight and Obese patients with varying renal (dys)function in the novel era of AUC 400\u2013600 mg\u00b7h\/L-Targeted dosing","volume":"63","author":"Zhang","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2025.102838_bib28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcp.14144","article-title":"Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals","volume":"86","author":"Smit","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2025.102838_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/phar.1531","article-title":"Pharmacokinetics of Vancomycin in extremely Obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy","volume":"35","author":"Adane","year":"2015","journal-title":"J Human Pharmacol Drug Ther"},{"key":"10.1016\/j.jiac.2025.102838_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11050224","article-title":"Application of pharmacometrics in pharmacotherapy: open-source software for Vancomycin therapeutic drug management","volume":"11","author":"Bae","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jiac.2025.102838_bib31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/FTD.0000000000000490","article-title":"Hospitalized patients with and without hemodialysis have markedly different vancomycin pharmacokinetics: a population pharmacokinetic model-based analysis","volume":"40","author":"Goti","year":"2018","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2025.102838_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/17425255.2022.2098106","article-title":"Review and evaluation of vancomycin dosing guidelines for obese individuals","volume":"18","author":"Wong","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jiac.2025.102838_bib33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00228-012-1340-4","article-title":"Decreased vancomycin clearance in patients with congestive heart failure","volume":"69","author":"Shimamoto","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2025.102838_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/8755122515599553","article-title":"Identification of risk factors for initial elevated vancomyin trough concentrations","volume":"32","author":"MacDougall","year":"2016","journal-title":"J Pharm Technol"},{"key":"10.1016\/j.jiac.2025.102838_bib35","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s11095-024-03781-4","article-title":"Identification of patients who require two-point blood sampling for the peak and trough values rather than one-point blood sampling for the trough value for the evaluation of AUC of Vancomycin using bayesian estimation","volume":"41","author":"Suzuki","year":"2024","journal-title":"Pharm Res"},{"key":"10.1016\/j.jiac.2025.102838_bib36","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40266-024-01140-x","article-title":"Decreased kidney function explains higher Vancomycin exposure in older adults","volume":"41","author":"Edwina","year":"2024","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jiac.2025.102838_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1252757","article-title":"Model-informed precision dosing in vancomycin treatment","volume":"14","author":"Yoon","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiac.2025.102838_bib38","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/phar.4613","article-title":"Impacts of age and BMI on vancomycin model choice in a Bayesian software: lessons from a very large multi-site retrospective study","volume":"44","author":"Hughes","year":"2024","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:00:07Z","timestamp":1764324007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25002351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1341321X25002351"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102838","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and external validation of a population pharmacokinetic model and optimal Vancomycin dosing regimen for overweight and obese patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102838"}}